Zions Bancorporation N.A. Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Zions Bancorporation N.A. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 18.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,121 shares of the medical research company’s stock after purchasing an additional 1,594 shares during the period. Zions Bancorporation N.A.’s holdings in Charles River Laboratories International were worth $1,868,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Charles River Laboratories International by 6.1% during the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock valued at $124,394,000 after purchasing an additional 38,827 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent analyst reports. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Barclays cut their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Price Performance

CRL stock opened at $161.57 on Wednesday. The company has a fifty day simple moving average of $165.32 and a two-hundred day simple moving average of $183.30. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $273.32. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $8.26 billion, a P/E ratio of 1,077.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the company earned $2.46 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).